PMID- 25547117
OWN - NLM
STAT- MEDLINE
DCOM- 20160316
LR  - 20210331
IS  - 1952-4013 (Electronic)
IS  - 1167-1122 (Linking)
VI  - 25
IP  - 2
DP  - 2015 Apr
TI  - Pemphigus vulgaris: approach to treatment.
PG  - 103-13
LID - 10.1684/ejd.2014.2483 [doi]
AB  - The therapeutic management of pemphigus vulgaris (PV) is centered around 
      immunosuppression, which can be generalized, as in the use of corticosteroids or 
      steroid sparing agents, or specific, as in therapeutic blockage of autoantibody 
      production, certain cytokines, or signaling pathways. Currently, the backbone of 
      treatment for PV, particularly, first line therapy, remains systemic 
      corticosteroids. Although very effective, the significant side effects of 
      long-term corticosteroid usage are well documented. Adjunctive therapies aim to 
      eliminate, or at least decrease, the necessary dose of corticosteroids. 
      Specifically, azathioprine, cyclophosphamide, methotrexate, cyclosporine, 
      mycophenolate mofetil and dapsone are now widely used in PV. Intravenous 
      immunoglobulin (IVIG), plasmapheresis, immunoadsorption, and most recently, 
      rituximab, are other members of the therapeutic armamentarium. However, despite 
      the widening range of treatment options in PV, well-controlled clinical trials 
      and consensus guidelines are lacking.
FAU - Sinha, Animesh A
AU  - Sinha AA
AD  - Department of Dermatology, University of Buffalo 6078 Clinical and Translational 
      Research Center 875 Ellicott Street, Buffalo, NY 14203.
FAU - Hoffman, Melissa B
AU  - Hoffman MB
AD  - Department of Dermatology, University of Buffalo 6078 Clinical and Translational 
      Research Center 875 Ellicott Street, Buffalo, NY 14203.
FAU - Janicke, Elise C
AU  - Janicke EC
AD  - Department of Dermatology, University of Buffalo 6078 Clinical and Translational 
      Research Center 875 Ellicott Street, Buffalo, NY 14203.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Animals
MH  - B-Lymphocytes
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Immunotherapy
MH  - *Lymphocyte Depletion
MH  - Pemphigus/*therapy
MH  - Plasmapheresis
MH  - Rituximab/*therapeutic use
MH  - Signal Transduction/drug effects
MH  - T-Lymphocytes
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - immunosuppressive
OT  - immunotherapy
OT  - pemphigus vulgaris
OT  - rituximab
OT  - treatment
EDAT- 2014/12/31 06:00
MHDA- 2016/03/17 06:00
CRDT- 2014/12/31 06:00
PHST- 2014/12/31 06:00 [entrez]
PHST- 2014/12/31 06:00 [pubmed]
PHST- 2016/03/17 06:00 [medline]
AID - ejd.2014.2483 [pii]
AID - 10.1684/ejd.2014.2483 [doi]
PST - ppublish
SO  - Eur J Dermatol. 2015 Apr;25(2):103-13. doi: 10.1684/ejd.2014.2483.